XT
PSTV

XTX Topco’s Plus Therapeutics PSTV Stock Holding History

XTX Topco’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.9K Sell
4,641
-5,301
-53% -$40.2K ﹤0.01% 3563
2025
Q4 		$127K Buy
+9,942
New +$150K ﹤0.01% 2567

Other funds holding PSTV

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

XTX Topco's PSTV Position: Q1 2026 in Review

XTX Topco reduced its Plus Therapeutics (PSTV) stake by 53% in Q1 2026, selling an estimated $40.2K and leaving 4,641 shares worth $18.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3563.

XTX Topco first reported a position in PSTV in Q4 2025 and has held it in 2 quarters since. The position peaked at $127K in Q4 2025. 23 funds tracked by Wall St. Rank hold PSTV as of Q1 2026.

  • XTX Topco held 4,641 shares of Plus Therapeutics worth $18.9K as of Q1 2026.
  • XTX Topco sold 5,301 Plus Therapeutics shares in Q1 2026, an estimated $40.2K.
  • Plus Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3563 holding.
  • XTX Topco first reported a position in Plus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • XTX Topco's Plus Therapeutics position peaked at $127K in Q4 2025.
  • 23 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.